IVIG vs SCIG in CIDP
The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration
Rutgers, The State University of New Jersey
20 participants
Sep 11, 2022
INTERVENTIONAL
Conditions
Summary
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Eligibility
Inclusion Criteria2
- Patients aged \>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria).
- :1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG.
Exclusion Criteria7
- Patients receiving IVIG for indications other than CIDP will be excluded.
- Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \< 50 mL/min) will be excluded
- Active malignancies
- Diabetes
- Myasthenia gravis
- Immunodeficiency
- Autoimmune disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05584631